{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:52:56Z","timestamp":1791978776865,"version":"4.4.0"},"reference-count":302,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbcan.2026.189736","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T06:17:45Z","timestamp":1791785865000},"page":"189736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular landscape of chondrosarcoma: From tumor biology to therapeutic vulnerabilities"],"prefix":"10.1016","volume":"1881","author":[{"given":"Elisa","family":"Belluzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Pozzuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Trovarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189736_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.03.007","article-title":"Sarcoma\u2013The standard-bearer in cancer discovery","volume":"126","author":"Potter","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/0284186X.2018.1554260","article-title":"Chondrosarcoma in Norway 1990-2013; an epidemiological and prognostic observational study of a complete national cohort","volume":"58","author":"Thorkildsen","year":"2019","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"10.1016\/j.bbcan.2026.189736_bb0015","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00264-006-0212-x","article-title":"Pathology of primary malignant bone and cartilage tumours","volume":"30","author":"Rozeman","year":"2006","journal-title":"Int. Orthop."},{"key":"10.1016\/j.bbcan.2026.189736_bb0020","series-title":"WHO Classification of Tumours of Soft Tissue and Bone","author":"W.H. O. World Health Organization","year":"2013"},{"issue":"Suppl. 5","key":"10.1016\/j.bbcan.2026.189736_bb0025","doi-asserted-by":"crossref","first-page":"v204","DOI":"10.1093\/annonc\/mdq223","article-title":"Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Hogendoorn","year":"2010","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0030","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","article-title":"ESMO guidelines committee, PaedCan and ERN EURACAN, bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/ijms19010311","article-title":"Chondrosarcoma: a rare misfortune in aging human cartilage? The role of stem and progenitor cells in proliferation, malignant degeneration and therapeutic resistance","volume":"19","author":"Boehme","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0040","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Electronic address: clinicalguidelines@esmo.org, Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0045","first-page":"205","article-title":"Bone Cancer: diagnosis and treatment principles","volume":"98","author":"Ferguson","year":"2018","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.bbcan.2026.189736_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268215","article-title":"Chondrosarcoma patient characteristics, management, and outcomes based on over 5,000 cases from the National Cancer Database (NCDB)","volume":"17","author":"Ottesen","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189736_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116981","article-title":"Incidence and survival of primary bone sarcoma diagnosed in England between 1996 and 2020; an analysis from the National Disease Registration Service","volume":"246","author":"Hastings","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2340\/1651-226X.2026.45117","article-title":"Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU\u00ae cohort study","volume":"65","author":"Barchuk","year":"2026","journal-title":"Acta Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0065","series-title":"Bones and Joints Cancer: Pathology and Genetics","author":"Hogendoorn","year":"2019"},{"issue":"43","key":"10.1016\/j.bbcan.2026.189736_bb0070","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ejca.2007.06.016","article-title":"Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group","volume":"1990","author":"Grimer","year":"2007","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.bbcan.2026.189736_bb0075","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jso.23173","article-title":"Clinical outcome of central conventional chondrosarcoma","volume":"106","author":"Angelini","year":"2012","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jso.23351","article-title":"Survival analysis of patients with chondrosarcomas of the pelvis","volume":"108","author":"Mavrogenis","year":"2013","journal-title":"J. Surg. Oncol."},{"issue":"2009","key":"10.1016\/j.bbcan.2026.189736_bb0085","first-page":"1063","article-title":"Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database","volume":"91","author":"Giuffrida","year":"2026","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.bbcan.2026.189736_bb0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1302\/0301-620X.84B1.0840093","article-title":"Risk factors for survival and local control in chondrosarcoma of bone","volume":"84","author":"Fiorenza","year":"2002","journal-title":"J. Bone Joint Surg. (Br.)"},{"key":"10.1016\/j.bbcan.2026.189736_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00150","article-title":"Biomarkers of osteosarcoma, chondrosarcoma, and Ewing sarcoma","volume":"8","author":"Evola","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0100","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/ijms23031096","article-title":"Therapeutic targets and emerging treatments in advanced chondrosarcoma","volume":"23","author":"Miwa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0105","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.ejso.2018.05.033","article-title":"The role of surgical margins in chondrosarcoma","volume":"44","author":"Stevenson","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0110","doi-asserted-by":"crossref","first-page":"440","DOI":"10.52312\/jdrs.2022.526","article-title":"Evaluation of prognostic factors affecting survival in chondrosarcoma treatment and comparison with literature","volume":"33","author":"Co\u015fkun","year":"2022","journal-title":"Jt. Dis. Relat. Surg."},{"key":"10.1016\/j.bbcan.2026.189736_bb0115","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.15953.1","article-title":"Chondrosarcoma: biology, genetics, and epigenetics","volume":"7","author":"Chow","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.bbcan.2026.189736_bb0120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00223-017-0372-2","article-title":"Biology of bone sarcomas and new therapeutic developments","volume":"102","author":"Brown","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bbcan.2026.189736_bb0125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00590-014-1468-2","article-title":"State-of-the-art approach for bone sarcomas","volume":"25","author":"Mavrogenis","year":"2015","journal-title":"Eur. J. Orthop. Surg. Traumatol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104980","article-title":"Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy","volume":"159","author":"Zhu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0135","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1158\/1078-0432.CCR-21-1893","article-title":"Fresh tissue multi-omics profiling reveals immune classification and suggests immunotherapy candidates for conventional chondrosarcoma","volume":"27","author":"Li","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0140","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.3390\/cancers12123589","article-title":"Beyond the influence of IDH mutations: exploring epigenetic vulnerabilities in chondrosarcoma","volume":"12","author":"Venneker","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189736_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105075","article-title":"Chondrosarcoma: clinical behavior, molecular mechanisms, and emerging therapeutic strategies","volume":"218","author":"Agulnik","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2026.103197","article-title":"Chondrosarcoma: a comprehensive review of tumor biology, clinical behavior, and therapeutic advances","volume":"149","author":"Li","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2026.189736_bb0155","doi-asserted-by":"crossref","first-page":"977","DOI":"10.3390\/cells13110977","article-title":"Emerging treatments targeting the tumor microenvironment for advanced chondrosarcoma","volume":"13","author":"Ingangi","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189736_bb0160","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/cancers15061703","article-title":"Classification of chondrosarcoma: from characteristic to challenging imaging findings","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189736_bb0165","series-title":"WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours","year":"2020"},{"key":"10.1016\/j.bbcan.2026.189736_bb0170","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2018.09.001","article-title":"Chondrosarcoma: an overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets","volume":"131","author":"Nazeri","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/CCO.0000000000000300","article-title":"Molecular oncogenesis of chondrosarcoma: impact for targeted treatment","volume":"28","author":"Speetjens","year":"2016","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0180","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0185","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1302\/0301-620X.96B6.33037","article-title":"The presentation, treatment and outcome of periosteal chondrosarcoma in the Netherlands","volume":"96-B","author":"Goedhart","year":"2014","journal-title":"Bone Jt. J."},{"key":"10.1016\/j.bbcan.2026.189736_bb0190","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.2214\/AJR.08.1159","article-title":"Periosteal chondrosarcoma","volume":"192","author":"Chaabane","year":"2009","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0195","first-page":"199","article-title":"Survivorship analysis in patients with periosteal chondrosarcoma","volume":"448","author":"Papagelopoulos","year":"2006","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.bbcan.2026.189736_bb0200","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00428-002-0641-x","article-title":"Towards a new understanding and classification of chondrogenic neoplasias of the skeleton \u2013 biochemistry and cell biology of chondrosarcoma and its variants","volume":"441","author":"Aigner","year":"2002","journal-title":"Virchows Arch."},{"key":"10.1016\/j.bbcan.2026.189736_bb0205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00402-007-0353-4","article-title":"Clear cell chondrosarcoma of bone: long time follow-up of 18 cases","volume":"128","author":"Donati","year":"2008","journal-title":"Arch. Orthop. Trauma Surg."},{"key":"10.1016\/j.bbcan.2026.189736_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100267","article-title":"Clear cell chondrosarcoma is an underestimated tumor: report of 7 cases and meta-analysis of the literature","volume":"19","author":"Klein","year":"2019","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0215","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.semdp.2014.01.006","article-title":"Cartilage-forming tumors","volume":"31","author":"Qasem","year":"2014","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0220","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1440-1827.2010.02530.x","article-title":"Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas","volume":"60","author":"Dornauer","year":"2010","journal-title":"Pathol. Int."},{"key":"10.1016\/j.bbcan.2026.189736_bb0225","first-page":"106","article-title":"Dedifferentiated chondrosarcoma revisited","volume":"20","author":"Mavrogenis","year":"2011","journal-title":"J. Surg. Orthop. Adv."},{"key":"10.1016\/j.bbcan.2026.189736_bb0230","series-title":"Bone and Soft Tissue Tumors","author":"Campanacci","year":"1999"},{"key":"10.1016\/j.bbcan.2026.189736_bb0235","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.5858\/arpa.2020-0379-OA","article-title":"Targeted next-generation sequencing identifies molecular and genetic events in dedifferentiated chondrosarcoma","volume":"145","author":"Lucas","year":"2021","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.bbcan.2026.189736_bb0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/1078-0432.CCR-18-4212","article-title":"Genomic profiling identifies association of IDH1\/IDH2 mutation with longer relapse free and metastasis free survival in high-grade chondrosarcoma","volume":"26","author":"Zhu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-018-0668-z","article-title":"Mesenchymal chondrosarcoma: a review with emphasis on its fusion-driven biology","volume":"20","author":"El Beaino","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189736_bb0250","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/932451","article-title":"The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets","volume":"2011","author":"David","year":"2011","journal-title":"Sarcoma"},{"key":"10.1016\/j.bbcan.2026.189736_bb0255","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1265716","article-title":"Description of the immune microenvironment of chondrosarcoma and contribution to progression","volume":"6","author":"Simard","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2026.189736_bb0260","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcp.22245","article-title":"Hierarchical clustering of flow cytometry data for the study of conventional central chondrosarcoma","volume":"225","author":"Diaz-Romero","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0265","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(05)70282-5","article-title":"Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment","volume":"6","author":"Bov\u00e9e","year":"2005","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0270","first-page":"1103","article-title":"Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma","volume":"17","author":"Grimaud","year":"2002","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0275","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbcan.2026.189736_bb0280","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.3390\/cancers15092556","article-title":"Molecular in-depth characterization of chondrosarcoma for current and future targeted therapies","volume":"15","author":"Walter","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189736_bb0285","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","article-title":"Tumor angiogenesis: molecular pathways and therapeutic targets","volume":"17","author":"Weis","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189736_bb0290","first-page":"600","article-title":"Vascular pattern in enchondroma and chondrosarcoma: clinical and immunohistologic study","volume":"22","author":"Cintra","year":"2014","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"10.1016\/j.bbcan.2026.189736_bb0295","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.prp.2008.12.008","article-title":"Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors","volume":"205","author":"Kalinski","year":"2009","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbcan.2026.189736_bb0300","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0046-8177(00)80248-8","article-title":"Microvasculature and VEGF expression in cartilaginous tumors","volume":"31","author":"Ayala","year":"2000","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0305","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","article-title":"Angiogenesis in cancer","volume":"2","author":"Nishida","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.bbcan.2026.189736_bb0310","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00003086-200204000-00009","article-title":"Angiogenic cytokines in cartilage tumors","author":"McGough","year":"2002","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.bbcan.2026.189736_bb0315","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00129039-200609000-00013","article-title":"Diagnostic relevance of the immunohistochemical detection of growth factors in benign and malignant cartilaginous tumors","volume":"14","author":"Falcone","year":"2006","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"10.1016\/j.bbcan.2026.189736_bb0320","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/ijc.34842","article-title":"Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer","volume":"154","author":"Morita","year":"2024","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejmech.2018.08.060","article-title":"Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma","volume":"158","author":"Ghedira","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbcan.2026.189736_bb0330","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","article-title":"Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways","volume":"14","author":"Rohwer","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbcan.2026.189736_bb0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia Auckl"},{"key":"10.1016\/j.bbcan.2026.189736_bb0340","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1302\/0301-620X.90B3.19806","article-title":"Expression of hypoxia-inducible factor-1alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours","volume":"90","author":"Kubo","year":"2008","journal-title":"J. Bone Joint Surg. (Br.)"},{"key":"10.1016\/j.bbcan.2026.189736_bb0345","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jor.21193","article-title":"Increased levels of hypoxia-inducible factor-1\u03b1 are associated with Bcl-xL expression, tumor apoptosis, and clinical outcome in chondrosarcoma","volume":"29","author":"Chen","year":"2011","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0350","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10520295.2018.1556806","article-title":"Hypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors","volume":"94","author":"Kouvaras","year":"2019","journal-title":"Biotech. Histochem."},{"key":"10.1016\/j.bbcan.2026.189736_bb0355","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1038\/s41467-020-18817-7","article-title":"A system-level approach identifies HIF-2\u03b1 as a critical regulator of chondrosarcoma progression","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189736_bb0360","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13569-016-0053-3","article-title":"Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours","volume":"6","author":"Inagaki","year":"2016","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0365","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/ijms27042018","article-title":"Integrated immune and molecular profiling identifies prognostic subgroups and therapeutic targets in chondrosarcoma","volume":"27","author":"Zaj\u0105c","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0370","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2326-6066.CIR-25-1016","article-title":"Potent cytotoxic tumor-infiltrating lymphocytes can be generated from immune-excluded chondrosarcomas using Regulatable membrane-bound IL15","volume":"14","author":"Ao","year":"2026","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0375","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1158\/1078-0432.CCR-12-3647","article-title":"Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0380","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1101\/gr.160598.113","article-title":"Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma","volume":"24","author":"Totoki","year":"2014","journal-title":"Genome Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0385","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ng.2668","article-title":"Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma","volume":"45","author":"Tarpey","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2026.189736_bb0390","doi-asserted-by":"crossref","first-page":"998","DOI":"10.7150\/jca.22915","article-title":"IDH1\/2 mutations predict shorter survival in chondrosarcoma","volume":"9","author":"Lugowska","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0395","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/gcc.21974","article-title":"Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma","volume":"51","author":"Meijer","year":"2012","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0400","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11523-024-01115-3","article-title":"IDH1\/2 mutations in cancer: unifying insights and unlocking therapeutic potential for chondrosarcoma","volume":"20","author":"Deshmukh","year":"2025","journal-title":"Target. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0405","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1073\/pnas.1424400112","article-title":"Mutant IDH is sufficient to initiate enchondromatosis in mice","volume":"112","author":"Hirata","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2026.189736_bb0410","doi-asserted-by":"crossref","first-page":"12116","DOI":"10.1016\/S0021-9258(19)50315-5","article-title":"Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases","volume":"268","author":"Haselbeck","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189736_bb0415","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant Isocitrate dehydrogenase inhibitors as targeted cancer therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0420","doi-asserted-by":"crossref","first-page":"33946","DOI":"10.1074\/jbc.M404298200","article-title":"Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity","volume":"279","author":"Xu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189736_bb0425","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41388-017-0077-z","article-title":"Wild-type and mutated IDH1\/2 enzymes and therapy responses","volume":"37","author":"Molenaar","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189736_bb0430","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13578-017-0165-3","article-title":"Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight","volume":"7","author":"Al-Khallaf","year":"2017","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0435","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","article-title":"Biological role and therapeutic potential of IDH mutations in cancer","volume":"34","author":"Waitkus","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189736_bb0440","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0445","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/JBM.S70716","article-title":"IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives","volume":"7","author":"Mondesir","year":"2016","journal-title":"J. Blood Med."},{"key":"10.1016\/j.bbcan.2026.189736_bb0450","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw4543","article-title":"Cancer-associated mutation and beyond: the emerging biology of isocitrate dehydrogenases in human disease","volume":"5","author":"Tommasini-Ghelfi","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2026.189736_bb0455","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189736_bb0460","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbcan.2026.189736_bb0465","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189736_bb0470","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1101\/gad.198200.112","article-title":"D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function","volume":"26","author":"Sasaki","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2026.189736_bb0475","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7729968","article-title":"IDH1 mutation induces HIF-1\u03b1 and confers Angiogenic properties in chondrosarcoma JJ012 cells","volume":"2022","author":"Hu","year":"2022","journal-title":"Dis. Markers"},{"key":"10.1016\/j.bbcan.2026.189736_bb0480","doi-asserted-by":"crossref","first-page":"14832","DOI":"10.18632\/oncotarget.4024","article-title":"The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or \u22122 blocks osteoblast differentiation in vitro and in vivo","volume":"6","author":"Suijker","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0485","article-title":"Mutant IDH1 dysregulates the differentiation of mesenchymal stem cells in association with gene-specific histone modifications to cartilage- and bone-related genes","volume":"10","author":"Jin","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189736_bb0490","first-page":"217","article-title":"Isocitrate dehydrogenase 1 mutations (IDH1) and p16\/CDKN2A copy number change in conventional chondrosarcomas, Virchows arch. Int","volume":"466","author":"Amary","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0495","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13073-022-01084-0","article-title":"A genetic model for central chondrosarcoma evolution correlates with patient outcome","volume":"14","author":"Cross","year":"2022","journal-title":"Genome Med."},{"key":"10.1016\/j.bbcan.2026.189736_bb0500","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-23-1703","article-title":"Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals TP53 mutation to be associated with worse outcomes","volume":"29","author":"Denu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0505","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13569-017-0074-6","article-title":"IDH1 or \u22122 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas","volume":"7","author":"Cleven","year":"2017","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0510","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jos.2021.07.024","article-title":"Prognostic impact of IDH mutations in chondrosarcoma","volume":"27","author":"Nakagawa","year":"2022","journal-title":"J. Orthop. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0515","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/CORR.0000000000002960","article-title":"Are IDH1 R132 mutations associated with poor prognosis in patients with chondrosarcoma of the bone?","volume":"482","author":"Trovarelli","year":"2024","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.bbcan.2026.189736_bb0520","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pharmthera.2019.06.010","article-title":"TP53 in bone and soft tissue sarcomas","volume":"202","author":"Thoenen","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2026.189736_bb0525","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/jor.1100160510","article-title":"Chemotherapy and P-glycoprotein expression in chondrosarcoma","volume":"16","author":"Terek","year":"1998","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0530","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrc2869","article-title":"Cartilage tumours and bone development: molecular pathology and possible therapeutic targets","volume":"10","author":"Bov\u00e9e","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0535","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/j.1582-4934.2008.00406.x","article-title":"Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro","volume":"13","author":"Schrage","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189736_bb0540","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000893","article-title":"p53 research: the past thirty years and the next thirty years","volume":"2","author":"Lane","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0545","first-page":"257","article-title":"Possible association of p53 overexpression and mutation with high-grade chondrosarcoma","volume":"2","author":"Dobashi","year":"1993","journal-title":"Diagn. Mol. Pathol. Am. J. Surg. Pathol. Part B"},{"key":"10.1016\/j.bbcan.2026.189736_bb0550","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2324::AID-CNCR12>3.0.CO;2-U","article-title":"Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study","volume":"83","author":"Oshiro","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0555","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/1097-0142(19950715)76:2<223::AID-CNCR2820760210>3.0.CO;2-4","article-title":"p53 expression in dedifferentiated chondrosarcoma","volume":"76","author":"Simms","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0560","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/bjc.1993.493","article-title":"p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas","volume":"68","author":"Wadayama","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0565","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/0046-8177(95)90166-3","article-title":"p53 expression and DNA ploidy of cartilage lesions","volume":"26","author":"Coughlan","year":"1995","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0570","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<782::AID-IJC7>3.0.CO;2-O","article-title":"Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues","volume":"85","author":"Asp","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0575","first-page":"89","article-title":"Rb-loss is associated with high malignancy in chondrosarcoma","volume":"15","author":"R\u00f6pke","year":"2006","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189736_bb0580","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2026.189736_bb0585","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2026.189736_bb0590","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/bs.acr.2020.02.002","article-title":"Cyclin D-CDK4\/6 functions in cancer","volume":"148","author":"Gao","year":"2020","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0595","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41467-017-01173-4","article-title":"YEATS2 links histone acetylation to tumorigenesis of non-small cell lung cancer","volume":"8","author":"Mi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189736_bb0600","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.path.2017.04.005","article-title":"Integrating morphology and genetics in the diagnosis of cartilage tumors","volume":"10","author":"de Andrea","year":"2017","journal-title":"Surg. Pathol. Clin."},{"key":"10.1016\/j.bbcan.2026.189736_bb0605","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.18632\/oncotarget.26899","article-title":"Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma","volume":"10","author":"Qin","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0610","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3390\/biomedicines11071942","article-title":"Biomechanics of chondrocytes and Chondrons in healthy conditions and osteoarthritis: a review of the mechanical Characterisations at the microscale","volume":"11","author":"Pettenuzzo","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2026.189736_bb0615","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13023-023-03006-8","article-title":"Secondary peripheral chondrosarcoma in multiple osteochondromas: a retrospective single-institution case series","volume":"19","author":"Gnoli","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb0620","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/onc.2011.311","article-title":"Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT","volume":"31","author":"de Andrea","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2026.189736_bb0625","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/gcc.20937","article-title":"Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data","volume":"51","author":"Wang","year":"2012","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0630","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160279","article-title":"HEY1-NCOA2 expression modulates chondrogenic differentiation and induces mesenchymal chondrosarcoma in mice","volume":"8","author":"Tanaka","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbcan.2026.189736_bb0635","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/path.5899","article-title":"Genomic profiling identifies genes and pathways dysregulated by HEY1\u2013NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis","volume":"257","author":"Qi","year":"2022","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049705","article-title":"Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma","volume":"7","author":"Nyquist","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189736_bb0645","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.3390\/ijms24054539","article-title":"Epigenetic abnormalities in chondrosarcoma","volume":"24","author":"Bereza","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0650","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3390\/cancers17162689","article-title":"Advances in the molecular biology of chondrosarcoma for drug discovery and precision medicine","volume":"17","author":"Walker","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189736_bb0655","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbcan.2026.189736_bb0660","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1101\/gad.226753.113","article-title":"Induction of sarcomas by mutant IDH2","volume":"27","author":"Lu","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2026.189736_bb0665","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/2767-9764.CRC-22-0397","article-title":"Distinct IDH1\/2-associated methylation profile and enrichment of TP53 and TERT mutations distinguish dedifferentiated chondrosarcoma from conventional chondrosarcoma","volume":"3","author":"Dermawan","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189736_bb0670","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/path.1517","article-title":"Molecular analysis of the INK4A\/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression","volume":"202","author":"van Beerendonk","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0675","first-page":"2939","article-title":"Aberration of p73 promoter methylation in chondrosarcoma","volume":"37","author":"Liu","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0680","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10735-013-9511-x","article-title":"Loss of RUNX3 expression may contribute to poor prognosis in patients with chondrosarcoma","volume":"44","author":"Jin","year":"2013","journal-title":"J. Mol. Histol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0685","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41598-017-01763-8","article-title":"Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189736_bb0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbi.2018.08.020","article-title":"Epigenetic silencing of SFRP5 promotes the metastasis and invasion of chondrosarcoma by expression inhibition and Wnt signaling pathway activation","volume":"296","author":"Sheng","year":"2018","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bbcan.2026.189736_bb0695","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1096\/fj.09-136291","article-title":"Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells","volume":"24","author":"Bui","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.bbcan.2026.189736_bb0700","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1078\/0344-0338-00443","article-title":"Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma","volume":"199","author":"R\u00f6pke","year":"2003","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbcan.2026.189736_bb0705","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/598218","article-title":"Human chondrosarcoma cells acquire an epithelial-like gene expression pattern via an epigenetic switch: evidence for mesenchymal-epithelial transition during Sarcomagenesis","volume":"2011","author":"Fitzgerald","year":"2011","journal-title":"Sarcoma"},{"key":"10.1016\/j.bbcan.2026.189736_bb0710","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/1471-2407-10-471","article-title":"Microenvironment alters epigenetic and gene expression profiles in swarm rat chondrosarcoma tumors","volume":"10","author":"Hamm","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008340","article-title":"Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2\u2032-deoxycytidine results in increased tumorigenicity","volume":"4","author":"Hamm","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189736_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105090","article-title":"A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma","volume":"102","author":"Rey","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbcan.2026.189736_bb0725","doi-asserted-by":"crossref","DOI":"10.1002\/gcc.70160","article-title":"Accurate prediction of central conventional chondrosarcoma risk and outcome using methylation profiling: CHROME","volume":"65","author":"Cardoso","year":"2026","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0730","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098176","article-title":"3-deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells","volume":"9","author":"Girard","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189736_bb0735","doi-asserted-by":"crossref","first-page":"731","DOI":"10.33594\/000000168","article-title":"The Antitumoral effect of the S-Adenosylhomocysteine hydrolase inhibitor, 3-deazaneplanocin A, is independent of EZH2 but is correlated with EGFR downregulation in chondrosarcomas","volume":"53","author":"Aury-Landas","year":"2019","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189150","article-title":"Histone deacetylase complexes: structure, regulation and function","volume":"1879","author":"Asmamaw","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb0745","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1078-0432.CCR-06-1696","article-title":"The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells","volume":"13","author":"Sakimura","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0750","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1158\/1535-7163.MCT-21-0066","article-title":"Growth inhibition and induction of innate immune signaling of chondrosarcomas with epigenetic inhibitors","volume":"20","author":"Sheikh","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189736_bb0755","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2147\/CMAR.S254412","article-title":"Combination BET family protein and HDAC inhibition synergistically elicits chondrosarcoma cell apoptosis through RAD51-related DNA damage repair","volume":"12","author":"Huan","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102538","article-title":"HDAC inhibitor (SAHA) enhances B7-H3-specific CAR T cell cytotoxic efficacy against chondrosarcoma cells and prolongs survival in an orthotopic mouse model","volume":"62","author":"Osei-Hwedieh","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0765","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/nsr\/nwu008","article-title":"Non-coding RNA: a new frontier in regulatory biology","volume":"1","author":"Fu","year":"2014","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.bbcan.2026.189736_bb0770","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41576-023-00662-1","article-title":"Non-coding RNAs in disease: from mechanisms to therapeutics","volume":"25","author":"Nemeth","year":"2024","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbcan.2026.189736_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2023.100474","article-title":"YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522","volume":"39","author":"Green","year":"2023","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.154172","article-title":"Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs","volume":"239","author":"Roessner","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbcan.2026.189736_bb0785","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bcp.2018.05.001","article-title":"Resistin facilitates VEGF-C-associated lymphangiogenesis by inhibiting miR-186 in human chondrosarcoma cells","volume":"154","author":"Su","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0790","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1042\/CS20160117","article-title":"Adiponectin promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-27b through a CaMKII\/AMPK\/p38 signaling pathway in human chondrosarcoma cells","volume":"130","author":"Huang","year":"2016","journal-title":"Clin. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0795","doi-asserted-by":"crossref","first-page":"28647","DOI":"10.1038\/srep28647","article-title":"Leptin promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-27b in human chondrosarcoma cells","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189736_bb0800","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.354","article-title":"Brain-derived neurotrophic factor promotes VEGF-C-dependent lymphangiogenesis by suppressing miR-624-3p in human chondrosarcoma cells","volume":"8","author":"Lin","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb0805","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.3390\/ijms25105142","article-title":"Visfatin facilitates VEGF-D-induced Lymphangiogenesis through activating HIF-1\u03b1 and suppressing miR-2277-3p in human chondrosarcoma","volume":"25","author":"Song","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0810","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3390\/biomedicines9101330","article-title":"WISP-3 stimulates VEGF-C-dependent Lymphangiogenesis in human chondrosarcoma cells by inhibiting miR-196a-3p synthesis","volume":"9","author":"Lin","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2026.189736_bb0815","doi-asserted-by":"crossref","first-page":"38566","DOI":"10.18632\/oncotarget.9570","article-title":"Basic fibroblast growth factor promotes VEGF-C-dependent lymphangiogenesis via inhibition of miR-381 in human chondrosarcoma cells","volume":"7","author":"Tzeng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0820","doi-asserted-by":"crossref","first-page":"36896","DOI":"10.18632\/oncotarget.9213","article-title":"CCL5 promotes VEGF-C production and induces lymphangiogenesis by suppressing miR-507 in human chondrosarcoma cells","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0825","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41419-018-1241-2","article-title":"Resistin facilitates VEGF-A-dependent angiogenesis by inhibiting miR-16-5p in human chondrosarcoma cells","volume":"10","author":"Chen","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb0830","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.canlet.2016.10.010","article-title":"Amphiregulin enhances VEGF-A production in human chondrosarcoma cells and promotes angiogenesis by inhibiting miR-206 via FAK\/c-Src\/PKC\u03b4 pathway","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189736_bb0835","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.canlet.2014.11.015","article-title":"CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells","volume":"357","author":"Liu","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189736_bb0840","doi-asserted-by":"crossref","first-page":"10718","DOI":"10.18632\/oncotarget.2532","article-title":"CCL5 promotes VEGF-dependent angiogenesis by down-regulating miR-200b through PI3K\/Akt signaling pathway in human chondrosarcoma cells","volume":"5","author":"Liu","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0845","doi-asserted-by":"crossref","first-page":"39571","DOI":"10.18632\/oncotarget.17142","article-title":"WISP-3 inhibition of miR-452 promotes VEGF-A expression in chondrosarcoma cells and induces endothelial progenitor cells angiogenesis","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0850","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.3390\/cells11213470","article-title":"Visfatin-induced inhibition of miR-1264 facilitates PDGF-C synthesis in chondrosarcoma cells and enhances endothelial progenitor cell angiogenesis","volume":"11","author":"Song","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189736_bb0855","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1002\/1878-0261.12106","article-title":"Sphingosine-1-phosphate suppresses chondrosarcoma metastasis by upregulation of tissue inhibitor of metalloproteinase 3 through suppressing miR-101 expression","volume":"11","author":"Tsai","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0860","doi-asserted-by":"crossref","first-page":"258","DOI":"10.18632\/oncotarget.2724","article-title":"Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK\/p38 signaling pathway in human chondrosarcoma cells","volume":"6","author":"Tsai","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0865","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.31345","article-title":"NAMPT enhances LOX expression and promotes metastasis in human chondrosarcoma cells by inhibiting miR-26b-5p synthesis","volume":"239","author":"Lin","year":"2024","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0870","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/s41419-021-04392-2","article-title":"Nerve growth factor promotes lysyl oxidase-dependent chondrosarcoma cell metastasis by suppressing miR-149-5p synthesis","volume":"12","author":"Tzeng","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb0875","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.3390\/cancers13133347","article-title":"The mir-423-5p\/MMP-2 Axis regulates the nerve growth factor-induced promotion of chondrosarcoma metastasis","volume":"13","author":"Tzeng","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189736_bb0880","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbrc.2021.12.052","article-title":"YAP\/miR-524-5p axis negatively regulates TXNIP expression to promote chondrosarcoma cell growth","volume":"590","author":"Liu","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189736_bb0885","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2147\/OTT.S239887","article-title":"Upregulation of miR-211 promotes chondrosarcoma development via targeting tumor suppressor VHL","volume":"13","author":"Chen","year":"2020","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bbcan.2026.189736_bb0890","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1007\/s13277-015-4454-3","article-title":"The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2","volume":"37","author":"Jiang","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0895","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1007\/s13277-014-3026-2","article-title":"Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma, tumour biol","volume":"36","author":"Lu","year":"2015","journal-title":"J. Int. Soc. Oncodevelopmental Biol. Med."},{"key":"10.1016\/j.bbcan.2026.189736_bb0900","first-page":"571","article-title":"miR-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the ErbB2-regulated glucose metabolism","volume":"10","author":"Tang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bbcan.2026.189736_bb0905","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/jbmr.3976","article-title":"The miR-143\/145 cluster, a novel diagnostic biomarker in chondrosarcoma, acts as a tumor suppressor and directly inhibits Fascin-1","volume":"35","author":"Urdinez","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0910","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/03008207.2019.1702650","article-title":"mir-21-5p inhibits the progression of human chondrosarcoma by regulating CCR7\/STAT3\/NF-\u03baB pathway","volume":"62","author":"Li","year":"2021","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0915","doi-asserted-by":"crossref","first-page":"70232","DOI":"10.18632\/oncotarget.11835","article-title":"Endothelin-1 promotes epithelial-mesenchymal transition in human chondrosarcoma cells by repressing miR-300","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0920","doi-asserted-by":"crossref","first-page":"26216","DOI":"10.18632\/oncotarget.4460","article-title":"MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0925","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.7150\/ijbs.106827","article-title":"Ugonin inhibits chondrosarcoma metastasis through suppressing cathepsin V via promoting miR-4799-5p expression","volume":"21","author":"Tran","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0930","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1541-7786.MCR-14-0697","article-title":"miR-181a targets RGS16 to promote chondrosarcoma growth, angiogenesis, and metastasis","volume":"13","author":"Sun","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb0935","first-page":"2384","article-title":"The expression of miR-181a-5p and miR-371b-5p in chondrosarcoma","volume":"19","author":"Mutlu","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb0940","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s11999-014-3842-0","article-title":"MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells","volume":"473","author":"Sun","year":"2015","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.bbcan.2026.189736_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2026.100761","article-title":"MiRNA-based expression signatures in differential diagnosis of enchondroma and chondrosarcoma","volume":"58","author":"Walter","year":"2026","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0950","doi-asserted-by":"crossref","DOI":"10.1177\/1559325820920525","article-title":"Analysis of cells proliferation and MicroRNAs expression profile in human chondrosarcoma SW1353 cells exposed to Iodine-125 seeds irradiation","volume":"18","author":"Li","year":"2020","journal-title":"Dose-Response"},{"key":"10.1016\/j.bbcan.2026.189736_bb0955","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12672-024-01038-5","article-title":"MiR-6839-5p inhibits cell proliferation, migration and invasion; a possible correlation with the suppressing VEGFA expression in human chondrosarcoma cells","volume":"15","author":"Li","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb0960","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1177\/1535370217700735","article-title":"Long non-coding RNA BCAR4 promotes chondrosarcoma cell proliferation and migration through activation of mTOR signaling pathway","volume":"242","author":"Shui","year":"2017","journal-title":"Exp. Biol. Med. Maywood NJ"},{"key":"10.1016\/j.bbcan.2026.189736_bb0965","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41419-020-03352-6","article-title":"SP1-induced long non-coding RNA SNHG6 facilitates the carcinogenesis of chondrosarcoma through inhibiting KLF6 by recruiting EZH2","volume":"12","author":"Pu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb0970","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.31","article-title":"Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth","volume":"8","author":"Bao","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb0975","first-page":"2143","article-title":"Metastasis-associated lung adenocarcinoma transcript 1 promotes the proliferation of chondro&shy;sarcoma cell via activating Notch-1 signaling pathway","volume":"9","author":"Xu","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bbcan.2026.189736_bb0980","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.2147\/OTT.S244652","article-title":"Exosomal lncRNA RAMP2-AS1 derived from chondrosarcoma cells promotes angiogenesis through miR-2355-5p\/VEGFR2 Axis","volume":"13","author":"Cheng","year":"2020","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bbcan.2026.189736_bb0985","article-title":"Long noncoding RNA TUG1 promotes chondrosarcoma progression and M2 polarization","volume":"12","author":"Li","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb0990","doi-asserted-by":"crossref","first-page":"43557","DOI":"10.18632\/oncotarget.9618","article-title":"Targeted next-generation sequencing of dedifferentiated chondrosarcoma in the skull base reveals combined TP53 and PTEN mutations with increased proliferation index, an implication for pathogenesis","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb0995","first-page":"22","article-title":"PTEN mutation is rare in chondrosarcoma","volume":"11","author":"Lin","year":"2002","journal-title":"Diagn. Mol. Pathol. Am. J. Surg. Pathol. Part B"},{"key":"10.1016\/j.bbcan.2026.189736_bb1000","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-012-1968-x","article-title":"Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas","volume":"70","author":"Bernstein-Molho","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1005","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1158\/0008-5472.CAN-08-4801","article-title":"Kinome profiling of chondrosarcoma reveals Src-pathway activity and Dasatinib as option for treatment","volume":"69","author":"Schrage","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb1010","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/bjc.2013.451","article-title":"Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells","volume":"109","author":"van Oosterwijk","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1020","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/404810","article-title":"MAPK\/ERK signaling in osteosarcomas, Ewing sarcomas and chondrosarcomas: therapeutic implications and future directions","volume":"2012","author":"Chandhanayingyong","year":"2012","journal-title":"Sarcoma"},{"key":"10.1016\/j.bbcan.2026.189736_bb1025","doi-asserted-by":"crossref","first-page":"8642","DOI":"10.3390\/ijms22168642","article-title":"Visfatin promotes the metastatic potential of chondrosarcoma cells by stimulating AP-1-dependent MMP-2 production in the MAPK pathway","volume":"22","author":"Hung","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb1030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1476-4598-9-17","article-title":"CXCR4\/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression","volume":"9","author":"Sun","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1035","doi-asserted-by":"crossref","first-page":"41854","DOI":"10.1038\/s41598-025-25820-9","article-title":"Reduced 5-hydroxymethylcytosine due to TET2 downregulation is associated with chondrosarcoma progression","volume":"15","author":"Furukawa","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189736_bb1040","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2353\/ajpath.2006.050001","article-title":"Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation","volume":"168","author":"Tiet","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/path.2127","article-title":"Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas","volume":"211","author":"Hameetman","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1050","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1086\/302532","article-title":"EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas","volume":"65","author":"Bov\u00e9e","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbcan.2026.189736_bb1055","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/labinvest.3780202","article-title":"Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma","volume":"80","author":"Bov\u00e9e","year":"2000","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1060","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1093\/annonc\/mdt391","article-title":"GDC-0449 in patients with advanced chondrosarcomas: a French sarcoma group\/US and French National Cancer Institute single-arm phase II collaborative study","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1065","author":"Clinical Trials Register"},{"key":"10.1016\/j.bbcan.2026.189736_bb1070","article-title":"Elevated levels of Dickkopf-1 are associated with \u03b2-catenin accumulation and poor prognosis in patients with chondrosarcoma","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189736_bb1075","doi-asserted-by":"crossref","first-page":"17570","DOI":"10.18632\/oncotarget.4100","article-title":"Aberrant activation of Wnt\/\u03b2-catenin signaling drives proliferation of bone sarcoma cells","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb1080","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2353\/ajpath.2009.080623","article-title":"Aberrant Heparan sulfate proteoglycan localization, despite Normal Exostosin, in central chondrosarcoma","volume":"174","author":"Schrage","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1085","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ajpath.2012.12.036","article-title":"Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGF\u03b2 as potential targets","volume":"182","author":"van Oosterwijk","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1090","doi-asserted-by":"crossref","first-page":"30094","DOI":"10.18632\/oncotarget.8979","article-title":"TAZ and YAP are frequently activated oncoproteins in sarcomas","volume":"7","author":"Fullenkamp","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb1095","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/mc.23108","article-title":"PRMT1 potentiates chondrosarcoma development through activation of YAP activity","volume":"58","author":"Chen","year":"2019","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bbcan.2026.189736_bb1100","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/jcb.25863","article-title":"The BET Bromodomain inhibitor JQ1 suppresses chondrosarcoma cell growth via regulation of YAP\/p21\/c-Myc signaling","volume":"118","author":"Zhang","year":"2017","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bbcan.2026.189736_bb1105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41419-021-03416-1","article-title":"Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb1110","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41419-022-04916-4","article-title":"Mice with Trp53 and Rb1 deficiency in chondrocytes spontaneously develop chondrosarcoma via overactivation of YAP signaling","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb1115","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41419-024-07264-7","article-title":"KDELR1 regulates chondrosarcoma drug resistance and malignant behavior through Intergrin-hippo-YAP1 axis","volume":"15","author":"Yin","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2026.189736_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2026.100785","article-title":"Targeting the hippo\/YAP-TAZ pathway increases X-ray sensitivity in chondrosarcoma spheroids and is associated with autophagic disruption","volume":"59","author":"Lohberger","year":"2026","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2613.2010.00749.x","article-title":"Therapeutic molecular targets in human chondrosarcoma","volume":"91","author":"Jamil","year":"2010","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrrheum.2012.36","article-title":"Hypoxia-driven pathways in bone development, regeneration and disease","volume":"8","author":"Maes","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1135","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.orthres.2004.03.002","article-title":"Hypoxia induces HIF-1\u03b1 and VEGF expression in chondrosarcoma cells and chondrocytes","volume":"22","author":"Lin","year":"2004","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb1140","article-title":"Decoupling NAD+ metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2\u03b1 axis","volume":"5","author":"Suh","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189736_bb1145","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00428-001-0544-2","article-title":"Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone","volume":"440","author":"Masi","year":"2002","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1150","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/1471-2407-12-488","article-title":"BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors","volume":"12","author":"Boeuf","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1155","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/path.2008","article-title":"Peripheral chondrosarcoma progression is accompanied by decreased Indian hedgehog signalling","volume":"209","author":"Hameetman","year":"2006","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1160","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bcp.2007.11.017","article-title":"TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells","volume":"75","author":"Yeh","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1165","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/jcp.21568","article-title":"BMP-2 increases migration of human chondrosarcoma cells via PI3K\/Akt pathway","volume":"217","author":"Fong","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1170","doi-asserted-by":"crossref","first-page":"13494","DOI":"10.1038\/s41598-017-13994-w","article-title":"TGF-\u03b2 signalling and PEG10 are mutually exclusive and inhibitory in chondrosarcoma cells","volume":"7","author":"Shinohara","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189736_bb1175","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00774-018-0946-8","article-title":"PEG10 counteracts signaling pathways of TGF-\u03b2 and BMP to regulate growth, motility and invasion of SW1353 chondrosarcoma cells","volume":"37","author":"Yahiro","year":"2019","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bbcan.2026.189736_bb1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100222","article-title":"Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway","volume":"15","author":"Addie","year":"2019","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27125307","article-title":"Lipid metabolic reprogramming and epigenetic co-dysregulation across the central chondrosarcoma grade Spectrum: a multi-cohort RNA-seq study","volume":"27","author":"Ayhan","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb1190","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/s41416-018-0050-9","article-title":"Targeting glutaminolysis in chondrosarcoma in context of the IDH1\/2 mutation","volume":"118","author":"Peterse","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1195","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/onco6010016","article-title":"Metabolic reprogramming following mitochondrial transfer between IDH2-mutant chondrosarcoma cells and a normal B-cell line","volume":"6","author":"Wyckoff","year":"2026","journal-title":"Onco"},{"key":"10.1016\/j.bbcan.2026.189736_bb1200","doi-asserted-by":"crossref","first-page":"0026","DOI":"10.34133\/cancomm.0026","article-title":"Targeting grade-specific endoplasmic reticulum stress vulnerabilities in chondrosarcoma: divergent roles of protein kinase R-like endoplasmic reticulum kinase and inositol-requiring enzyme 1\u03b1 signaling","volume":"46","author":"Chen","year":"2026","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bbcan.2026.189736_bb1205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.772263","article-title":"Metabolic pathways and targets in chondrosarcoma","volume":"11","author":"Micaily","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1210","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1215","first-page":"241","article-title":"A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system","author":"Enneking","year":"1993","journal-title":"Clin. Orthop."},{"key":"10.1016\/j.bbcan.2026.189736_bb1220","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma","volume":"13","author":"Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189736_bb1225","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2021.04.017","article-title":"Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: results from the EUROpean bone over 40 sarcoma study","volume":"151","author":"Hompland","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1230","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1634\/theoncologist.2017-0574","article-title":"Outcome of first-line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma","volume":"24","author":"van Maldegem","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2026.189736_bb1235","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106080","article-title":"Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian sarcoma group network","volume":"11","author":"Baldi","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbcan.2026.189736_bb1240","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/curroncol32110615","article-title":"Chemotherapy strategies and their efficacy for mesenchymal chondrosarcoma","volume":"32","author":"Remiszewski","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1245","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4878512","article-title":"Revisiting the role of radiation therapy in chondrosarcoma: a National Cancer Database Study","volume":"2019","author":"Catanzano","year":"2019","journal-title":"Sarcoma"},{"key":"10.1016\/j.bbcan.2026.189736_bb1250","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.radonc.2018.06.040","article-title":"Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy","volume":"129","author":"Weber","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1255","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1002\/cncr.31298","article-title":"High control rates of proton- and carbon-ion\u2013beam treatment with intensity-modulated active raster scanning in 101 patients with skull base chondrosarcoma at the Heidelberg ion beam therapy center","volume":"124","author":"Mattke","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1260","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/cncr.28606","article-title":"High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results","volume":"120","author":"Uhl","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1265","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11060-020-03464-1","article-title":"Carbon ion radiotherapy for skull base chordomas and chondrosarcomas: a systematic review and meta-analysis of local control, survival, and toxicity outcomes","volume":"147","author":"Lu","year":"2020","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1270","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jor.24176","article-title":"Variations in contents of hyaluronan in the peritumoral micro-environment of human chondrosarcoma","volume":"37","author":"Fede","year":"2019","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb1275","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/jor.23794","article-title":"Suppression of hyaluronan synthesis attenuates the tumorigenicity of low-grade chondrosarcoma","volume":"36","author":"Hamada","year":"2018","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb1280","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/labinvest.2013.101","article-title":"New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance","volume":"93","author":"Monderer","year":"2013","journal-title":"Lab. Investig."},{"key":"10.1016\/j.bbcan.2026.189736_bb1285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181340","article-title":"Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing","volume":"12","author":"Voissiere","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189736_bb1290","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1208\/s12248-015-9757-1","article-title":"Multidrug Resistance Proteins (MRPs) and cancer therapy","volume":"17","author":"Zhang","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.bbcan.2026.189736_bb1295","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jor.1100170619","article-title":"Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance","volume":"17","author":"Wyman","year":"1999","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb1300","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1600-0463.2010.02656.x","article-title":"Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas","volume":"118","author":"S\u00f6derstr\u00f6m","year":"2010","journal-title":"APMIS"},{"key":"10.1016\/j.bbcan.2026.189736_bb1305","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbrc.2004.12.186","article-title":"Suppression of chondrosarcoma cells by 15-deoxy-Delta 12,14-prostaglandin J2 is associated with altered expression of Bax\/Bcl-xL and p21","volume":"328","author":"Shen","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189736_bb1310","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/annonc\/mdr512","article-title":"Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance","volume":"23","author":"van Oosterwijk","year":"2012","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1315","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1159\/000550731","article-title":"The anti-apoptotic protein lifeguard is expressed in osteosarcoma, chondrosarcoma, and soft tissue sarcoma","volume":"104","author":"Senger","year":"2026","journal-title":"Oncology"},{"key":"10.1016\/j.bbcan.2026.189736_bb1320","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/1878-0261.70002","article-title":"TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis","volume":"19","author":"Islam","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1325","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/CBM-160102","article-title":"Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells","volume":"18","author":"Huang","year":"2017","journal-title":"Cancer Biomark. Sect. Dis. Markers"},{"key":"10.1016\/j.bbcan.2026.189736_bb1330","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.3390\/cancers18172889","article-title":"The immune landscape of chondrosarcoma: a review of tumor-related immune cells","volume":"18","author":"Silvaggio","year":"2026","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2026.189736_bb1335","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/ijms24010839","article-title":"MicroRNA-631 Resensitizes doxorubicin-resistant chondrosarcoma cells by targeting Apelin","volume":"24","author":"Chen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb1340","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7314\/APJCP.2014.15.2.917","article-title":"MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR","volume":"15","author":"Zhu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.bbcan.2026.189736_bb1345","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.critrevonc.2018.03.009","article-title":"Biological aspects of chondrosarcoma: leaps and hurdles","volume":"126","author":"Mery","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1350","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3390\/cimb48050450","article-title":"Proton irradiation induces differential cellular responses and proteomic signatures in chondrosarcoma and chondrocytes","volume":"48","author":"Tudor","year":"2026","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1355","doi-asserted-by":"crossref","first-page":"18637","DOI":"10.18632\/oncotarget.24746","article-title":"Molecular mechanism of bystander effects and related abscopal\/cohort effects in cancer therapy","volume":"9","author":"Wang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189736_bb1360","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.ijrobp.2012.02.052","article-title":"Differential bystander signaling between radioresistant chondrosarcoma cells and fibroblasts after x-ray, proton, iron ion and carbon ion exposures","volume":"84","author":"Wakatsuki","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2026.189736_bb1365","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4103\/jcrt.jcrt_2269_23","article-title":"New advances in the treatment of chondrosarcoma under the PD-1\/PD-L1 pathway","volume":"20","author":"Yin","year":"2024","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.bbcan.2026.189736_bb1370","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3390\/ijms26041542","article-title":"Chondrosarcoma: new molecular insights, challenges in near-patient preclinical modeling, and therapeutic approaches","volume":"26","author":"Landuzzi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189736_bb1375","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3390\/cells15050392","article-title":"Vasculogenic mimicry: a potential therapeutic target for chondrosarcoma therapy","volume":"15","author":"Ingangi","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2026.189736_bb1380","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cncr.25632","article-title":"A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-\u03b1 or -\u03b2: an Italian sarcoma group study","volume":"117","author":"Grignani","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1385","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cncr.32515","article-title":"Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma","volume":"126","author":"Chow","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1390","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.03.039","article-title":"Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study","volume":"150","author":"Duffaud","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1395","article-title":"Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial","volume":"6","author":"Li","year":"2025","journal-title":"Med. N. Y."},{"key":"10.1016\/j.bbcan.2026.189736_bb1400","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-23-0974","article-title":"Preclinical characterization and phase I trial results of INBRX-109, A third-generation, recombinant, humanized, death receptor 5 agonist antibody, in chondrosarcoma","volume":"29","author":"Subbiah","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb1405","doi-asserted-by":"crossref","first-page":"11504","DOI":"10.1200\/JCO.2026.44.16_suppl.11504","article-title":"The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study","volume":"44","author":"Gelderblom","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1410","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase I study of the mutant IDH1 inhibitor Ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1415","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/1078-0432.CCR-24-4128","article-title":"Phase I study of the mutant IDH1 inhibitor Ivosidenib: long-term safety and clinical activity in patients with conventional chondrosarcoma","volume":"31","author":"Tap","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb1420","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS11582","article-title":"Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER)","volume":"43","author":"Wagner","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1425","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41467-026-68716-6","article-title":"Olutasidenib in recurrent\/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b\/2 trial","volume":"17","author":"Jones","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189736_bb1430","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2217\/fon-2016-0226","article-title":"Novel therapeutic approaches in chondrosarcoma","volume":"13","author":"Polychronidou","year":"2017","journal-title":"Future Oncol. Lond. Engl."},{"key":"10.1016\/j.bbcan.2026.189736_bb1435","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1440","doi-asserted-by":"crossref","first-page":"11533","DOI":"10.1200\/JCO.2023.41.16_suppl.11533","article-title":"A phase 2 study of an anti\u2013PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma","volume":"41","author":"Salkeni","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1445","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1038\/s41467-022-30874-8","article-title":"Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma","volume":"13","author":"D'Angelo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189736_bb1450","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","article-title":"Assessment of doxorubicin and Pembrolizumab in patients with advanced anthracycline-naive sarcoma: a phase 1\/2 nonrandomized clinical trial","volume":"6","author":"Pollack","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100271","article-title":"The immune landscape of chondrosarcoma - potential for therapeutic targeting of CSFR1+ macrophages","volume":"20","author":"Richert","year":"2020","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1460","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35628","article-title":"Nivolumab and sunitinib in patients with advanced bone sarcomas: a multicenter, single-arm, phase 2 trial","volume":"131","author":"Palmerini","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189736_bb1465","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12964-019-0327-5","article-title":"Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target","volume":"17","author":"Ouyang","year":"2019","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2026.189736_bb1470","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.3390\/cimb46110751","article-title":"Genetics and molecular pathogenesis of the chondrosarcoma: a review of the literature","volume":"46","author":"Iacobescu","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1475","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189736_bb1480","author":"Charlson"},{"key":"10.1016\/j.bbcan.2026.189736_bb1485","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130394","article-title":"A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT","volume":"129","author":"Siriki","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2026.189736_bb1490","doi-asserted-by":"crossref","first-page":"11526","DOI":"10.1200\/JCO.2024.42.16_suppl.11526","article-title":"Correlative results from NCI CTEP\/ETCTN 10330: a phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine\/cedazuridine) for advanced conventional chondrosarcoma (cCS)","volume":"42","author":"Lacuna","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189736_bb1495","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/jbmr.4532","article-title":"Distinct roles of glutamine metabolism in benign and malignant cartilage tumors with IDH mutations","volume":"37","author":"Zhang","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb1500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154680","article-title":"Receptor-activator of nuclear KappaB ligand expression as a new therapeutic target in primary bone tumors","volume":"11","author":"Yamagishi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2026.189736_bb1505","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/jor.22714","article-title":"Osteoclast inhibition impairs chondrosarcoma growth and bone destruction: chondrosarcoma growth and bone destruction","volume":"32","author":"Otero","year":"2014","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bbcan.2026.189736_bb1510","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3390\/biomedicines14092031","article-title":"Clinical, radiological, and biochemical evaluation in orthopedics: lessons from a special issue","volume":"14","author":"Biz","year":"2026","journal-title":"Biomedicines"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26002088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26002088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:32:03Z","timestamp":1791977523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26002088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":302,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0304419X26002088"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189736","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular landscape of chondrosarcoma: From tumor biology to therapeutic vulnerabilities","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189736"}}